Provider Alerts (Policy, Billing, or Coverage Update) - 2020
Metformin Extended Release (ER) Recall: Prescribing Alternative Products
Earlier this year, the Food and Drug Administration (FDA) began alerting patients and providers on the recall of generic extended release (ER) metformin medications. This was due to testing results that show N-Nitrosodimethylamine (NDMA) above the acceptable intake limit. As a result, many providers have shifted to prescribing brand name ER metformin, including Glumetza, Glucophage XR, and Fortamet.
Healthfirst is advising that all providers avoid prescribing brand name ER metformin because it has a high copay for Healthfirst members and may lead to non-adherence of these important medications.
